Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders.
We're delighted to feature in @thisismoney in today's @MailOnline
SMALL CAP IDEA: Ketamine drip therapy firm is taking on alcoholism
Covers our #AUD (SVN-001 & SVN-002) and #PTSD (SVN-SDN-14) prgrms
🔗 https://t.co/tsOrpdwRUi
@proactive_x@ProfDavidNutt @AnthonyTennyson
Our CEO, @AnthonyTennyson, cuaght up with @ZaksTradersCafe earlier today to provide details on our recent progress in drug discovery for #PTSD and drug development for #AUD
👂have a listen!
@Solvonis@ProfDavidNutt
Over 300M people will experience #PTSD in their lifetime. Yet first-line treatments fall short.
@SolvonisTx (LSE: SVNS) is developing new medicines for chronic, high-prevalence diseases like PTSD — where effective options remain limited.
#MentalHealth#Solvonis
Solvonis (LSE: SVNS) is aligned with the neursychiatry market reset
- ATAI, CMPS, MNMD, GHRS up 35–75% - Spravato hits $1.3B run rate - RFK Jr. calls for FDA reform
$SVNS Clinically active, capital disciplined, CNS-focused
#Biotech#CNS#AUD#PTSD#505b2#SVNS#MentalHealth
Solvonis (LSE: SVNS) is advancing SVN‑002, a sublingual esketamine OTF, for mod.-to-severe AUD — ~66% of the 29M US cases - targeting 505b2 to Spravato
Spravato, approved for TRD (~4–6M), hit $320M Q2 sales. J&J now guiding $3B–$3.5B peak.
📈 Bigger need. Clear precedent.
Solvonis is advancing SVN‑002 under the FDA’s 505(b)(2) pathway, referencing J&J’s $1B+ blockbuster Spravato®.
SVN‑002 targets moderate-to-severe #AUD with a differentiated formulation for addiction clinics.
#SVN002#505b2#Spravato#AddictionTreatment#Solvonis
AUD is the crisis we keep ignoring.
29.5M Americans meet criteria for AUD
<5% get treatment.
SVN‑002 is our neuroscience-led response:
✔ Novel esketamine therapeutic
✔ Clinic-based
✔ 505(b)(2) path, bridging to Spravato®
#AUD#SVN002#505b2#AddictionTreatment#Solvonis
Congrats to @SolvonisTx Chair, Dennis Purcell, on landmark $1.9B @AbbVie–IGI deal
As a Board Director at IGI, he played a key role in one of biotech’s biggest licensing agrmnts of 2025
🔹$700M upfront
🔹$1.225B in milestones
🔹Tiered royalties
Proud to have him lead Solvonis
@SolvonisTx Chair Purcell joins Levin & Papadopoulos for a Lucid Capital Mrkts exclusive
Three of biotechs most influential voices
Must-watch conversation
📅 July 17 | 2PM ET 🎙️ Hosted by Elemér Piros
Proud to have Dennis lead Solvonis
#SVNS#Biotech#AIinBiotech#CNS
The burden of Severe AUD is staggering & urgent
📊 40M w/ AUD across US UK EU4
➡️ ~13M w/ Severe AUD
💀 300K+ deaths/yr
💷 £27.4B/yr in England alone
@Solvonis_Tx is advancing SVN‑001 — a Phase 3 treatment aiming to change this.
🔗 https://t.co/lsqByp6k4h
$SVNS #AUD#SVN001
Solvonis (LSE: $SVNS) is pleased to announce that @Singer_CM has initiated research coverage.
The note, “Psyching Up for Success”, is authored by Dr. Karl Keegan, Head of Life Sciences Research.
Avail to institutional investors now; public next week.
https://t.co/Fh4NsoYJA0
At Solvonis (LSE: SVNS), USPTO has allowed a core patent (No. 18/838,986) for novel #CNS compounds in our #AI-enabled discovery prgm
-No objections -Indications: depression, stimulant use disorder -US exclusivity to ≥2043
$SVNS #Biotech#MentalHealth
https://t.co/mJWcidcPWr